Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | PDE8B | O95263 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30803666 | 0.89 | PARP1 (0.53) | PARP1NR1H2NR1H3PDE8BHSD17B10 | |
| SCHEMBL24543368 | 0.89 | PARP1 (0.53) | PARP1NR1H2NR1H3PDE8BHSD17B10 | |
| SCHEMBL4309075 | 0.87 | PARP1 (0.52) | PARP1CA1CA2CA4CA9 | |
| SCHEMBL4856306 | 0.87 | PARP1 (0.52) | PARP1CA1CA2CA4CA9 | |
| SCHEMBL4312622 | 0.87 | PARP1 (0.52) | PARP1CA1CA2CA4CA9 | |
| SCHEMBL1283375 | 0.87 | PARP1 (0.52) | PARP1CA1CA2CA4CA9 | |
| SCHEMBL5081566 | 0.87 | PARP1 (0.52) | PARP1CA1CA2CA4CA9 | |
| SCHEMBL8117710 | 0.87 | PARP1 (0.52) | PARP1CA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL38666438 | 0.86 | PARP1 (0.51) | PARP1CA1CA2CA4CA9 | |
| SCHEMBL16846148 | 0.86 | PARP1 (0.51) | PARP1CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3049417-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015017502-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| US-8791148-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-29 | — | — | US | disclosed |
| CN-101528712-B | Substituted benzimidazolone derivatives, medicaments containing them and the use thereof | ABBOTT GMBH & CO KG | 2013-10-30 | — | — | CN | disclosed |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8119676-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | Abbott GmbH & Co. HG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| CN-101528712-A | Substituted benzimidazolone derivatives, medicaments containing them and the use thereof | ABBOTT GMBH & CO KG (DE) | 2009-09-09 | — | — | CN | disclosed |
| EP-2061769-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008025736-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | PARP1 1693/4885CA1 2320/4885CA2 435/4885 |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | PARP1 1693/4885CA1 2320/4885CA2 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.